A RANDOMIZED, PHASE 2B STUDY OF SUNITINIB PLUS OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN (FOLFOX) VERSUS BEVACIZUMAB PLUS FOLFOX AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CANCER

Update Il y a 4 ans
Reference: EUCTR2007-002987-84

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To demonstrate an improvement in progression-free survival (PFS) in patients with mCRC treated with sunitinib plus FOLFOX compared with bevacizumab plus FOLFOX in the first-line treatment setting.


Inclusion criteria

  • Metastatic colorectal cancer